Pan-cancer genomic analysis reveals FOXA1 amplification is associated with adverse outcomes in non-small cell lung, prostate, and breast cancers. - Goglia AG; Alshalalfa M; Khan A; Isakov DR; Hougen HY; Swami N; Kannikal J; Mcbride SM; Gomez DR; Punnen S; Nguyen PL; Iyengar P; et al. (Journal of the National Cancer Institute, 2025)